Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial

Authors: Nobuya Inagaki, Masakazu Takeuchi, Tomonori Oura, Takeshi Imaoka, Yutaka Seino - The Lancet 2022 cited by 211